1. Home
  2. WDS vs NTRA Comparison

WDS vs NTRA Comparison

Compare WDS & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Woodside Energy Group Limited

WDS

Woodside Energy Group Limited

HOLD

Current Price

$16.12

Market Cap

31.3B

Sector

Energy

ML Signal

HOLD

Logo Natera Inc.

NTRA

Natera Inc.

HOLD

Current Price

$229.09

Market Cap

27.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WDS
NTRA
Founded
1954
2003
Country
Australia
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Medical Specialities
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
31.3B
27.0B
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
WDS
NTRA
Price
$16.12
$229.09
Analyst Decision
Hold
Strong Buy
Analyst Count
1
16
Target Price
N/A
$229.56
AVG Volume (30 Days)
584.7K
1.5M
Earning Date
08-18-2025
11-06-2025
Dividend Yield
6.29%
N/A
EPS Growth
58.72
N/A
EPS
1.54
N/A
Revenue
$13,781,000,000.00
$2,116,676,000.00
Revenue This Year
N/A
$32.77
Revenue Next Year
N/A
$16.51
P/E Ratio
$10.50
N/A
Revenue Growth
9.53
38.17
52 Week Low
$11.26
$125.38
52 Week High
$17.70
$246.90

Technical Indicators

Market Signals
Indicator
WDS
NTRA
Relative Strength Index (RSI) 41.36 56.44
Support Level $16.22 $225.58
Resistance Level $16.98 $246.90
Average True Range (ATR) 0.22 6.28
MACD -0.09 -2.50
Stochastic Oscillator 16.91 17.52

Price Performance

Historical Comparison
WDS
NTRA

About WDS Woodside Energy Group Limited

Incorporated in 1954 and named after the small Victorian town of Woodside, Woodside's early exploration focus moved from Victoria's Gippsland Basin to Western Australia's Carnarvon Basin. First LNG production from the North West Shelf came in 1984. BHP Billiton and Shell each had 40% shareholdings before BHP sold out in 1994 and Shell sold down to 34%. In 2017 Shell sold its entire shareholding. Woodside is one of the most LNG-leveraged companies globally.

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Share on Social Networks: